Development of Eurostars application

The underlying idea for value creation is to research and develop a unique and groundbreaking new method for treating cancer of plasma cells, multiple myeloma (MM). The goal of this project is to develop a nanovector by conjugating a beta-particle emittin g radionuclide to a tumour seeking carrier (affibody). The treatment would be effective on single cells and clusters of cells in the lymph nodes and should be excellently suited for treating MM. Malignant tumors can be irradiated with minimal damage to su rrounding healthy normal tissue by injecting the nanovector into the blood of patients. This technology aims to prolong progression free survival and improve the quality of life for people who suffer from hematologic cancer, in particular multiple myeloma . MM is not curable with current treatment. It is a cancer of plasma cells, a type of white blood cells normally responsible for producing antibodies. In MM, collections of abnormal plasma cells accumulate in the bone marrow, where they interfere with t he production of normal blood cells. Most cases of MM also feature the production of a paraprotein?an abnormal antibody which can cause kidney problems. Bone lesions and hypercalcemia (high calcium levels) are also often encountered.